Vr Adviser, LLC Corvus Pharmaceuticals, Inc. Transaction History

Vr Adviser, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$1.46 - $2.48 $365,000 - $620,000	-250,000 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$2.34 - $5.31 $7.44 Million - $16.9 Million	-3,177,461 Reduced 92.71%	250,000 $603,000
Q3 2021 Nov 15, 2021	BUY	$1.89 - $8.53 $6.48 Million - $29.2 Million	3,427,461 New	3,427,461 $16.6 Million

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $223M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Vr Adviser, LLC, based on Form 13F filings with the SEC.

Stay updated on Vr Adviser, LLC with notifications on news.